NCT00154323View on ClinicalTrials.gov

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Bipolar Disorder
Interventions
DRUG

Oxcarbazepine

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY